

Prescription & Enrollment Form

Vyvgart® and Vyvgart Hytrulo®

**accredo**  
677 Ala Moana Blvd., Suite 404,  
Honolulu, HI 96813 5412

Four simple steps to submit your referral.

# 1 Patient Information



Please provide copies of front and back of all medical and prescription insurance cards.

New patient Current patient

Patient's first name Last name Middle initial

Sex at birth: Male Female Gender identity Pronouns Last 4 digits of SSN

Date of birth Street address Apt #

City State Zip

Home phone Cell phone Email address

Parent/guardian (if applicable)

OK to leave message with alternate caregiver/contact

Patient's primary language: English Other If other, please specify

Insurance company Phone

Insured's name Insured's employer

Relationship to patient Identification # Policy/group #

Prescription card: Yes No If yes, carrier Policy # Group #:

Is patient eligible for Medicare? Yes No Does patient have secondary insurance? Yes No

**Provider will read the following statement to patient:** By providing the phone number(s) and email address above, you consent to receiving automated/artificial voice calls, emails and/or text messages from Accredo about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies.

# 2 Prescriber Information

All fields must be completed to expedite prescription fulfillment.

Prescriber's first name Last name

Prescriber's title If NP or PA, under direction of Dr.

Office address

Office contact and title

Office contact phone number Office contact email

Office/clinic/institution name Clinic/hospital affiliation

Street address Suite #

City State Zip

Phone Fax NPI # License #

Infusion location: Patient's home Office Infusion clinic Infusion clinic address:

Infusion clinic contact Phone Email address

# 3 Clinical Information

CHECK ONE

ICD-10 code (REQUIRED): G70.00 Myasthenia gravis without (acute) exacerbation G70.01: Myasthenia gravis with (acute) exacerbation

G61.81 Chronic inflammatory demyelinating polyneuropathy (CIPD) Other

MG-ADL\* score (if known) Is your patient new to therapy? Yes No

Other drugs used to treat the disease

Weight kg/lbs Height cm/in Date recorded

NKDA Known drug allergies

Concurrent meds

Adverse reactions with previous MG treatments?

If so, what MG treatment caused the reaction?

\*Myasthenia Gravis Activities of Daily Life

Patient's first name \_\_\_\_\_ Last name \_\_\_\_\_ Middle initial \_\_\_\_\_ Date of birth \_\_\_\_\_

Prescriber's first name \_\_\_\_\_ Last name \_\_\_\_\_ Phone \_\_\_\_\_

## 4 Prescribing Information

Medication	Route	Strength/Formulation	Directions
Vyvgart® vial	IV	400mg/20mL single-dose vial infusion	<p>Infuse _____ mg/kg OR _____ mg intravenously over one hour.</p> <p>Initial treatment cycle: 1 time weekly for 4 weeks, rounding to an easily measurable dose when clinically appropriate.</p> <p>Administer additional treatment cycle _____ weeks after the 1st dose in the previous cycle was administered and then repeat cycle moving forward.</p> <p>OR Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle. Additional prescription will be required.</p> <p><b>Vascular access:</b>    Peripheral    Central    Port</p> <p><b>Infusion method:</b>   Gravity    Pump</p>
Vyvgart Hytrulo® vial	SQ injection	1,008mg efgartigimod alfa/11,200 hyaluronidase units per 5.6mL single-dose vial injection	<p>Administer 1,008mg subcutaneously over 30 to 90 seconds. Vyvgart Hytrulo must only be administered by a healthcare professional.</p> <p>For CIDP diagnosis: Frequency: once weekly ongoing.</p> <p>For gMG diagnosis: Frequency: Initial Treatment cycle: 1 time weekly for 4 weeks.</p> <p>Additional treatment cycle _____ weeks after the 1st dose in the previous cycle was administered and then repeat cycle moving forward.</p> <p>OR Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle. Additional prescription will be required.</p>
Vyvgart Hytrulo® prefilled syringe	SQ injection	1000mg efgartigimod alfa/10,000 hyaluronidase units per 5mL prefilled syringe	<p>Administer 1000mg subcutaneously over 20 to 30 seconds. Vyvgart Hytrulo prefilled syringe may be administered by patients and/or caregivers after proper instruction in subcutaneous injection technique.</p> <p><b>For CIDP diagnosis:</b> Frequency: once weekly ongoing.</p> <p><b>For gMG diagnosis:</b> Frequency: Initial Treatment cycle: 1 time weekly for 4 weeks.</p> <p>Additional treatment cycle _____ weeks after the 1st dose in the previous cycle was administered and then repeat cycle moving forward.</p> <p>OR Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle. Additional prescription will be required.</p>

Other instructions \_\_\_\_\_

**Adverse reaction medications:** *(keep on hand at all times)*

- Epinephrine 0.3mg auto-injector 2-pk for patients weighing greater than or equal to 30kg. Administer intramuscularly as needed for severe anaphylactic reaction times one dose
- Epinephrine 0.15mg auto-injector 2-pk for patients weighing less than 30kg. Administer intramuscularly as needed for severe anaphylactic reaction times one dose
- Diphenhydramine 25mg by mouth for mild allergic reactions and 50mg for moderate to severe times one dose

**Flushing orders:** *(for Vyvgart IV only)*

- 0.9% Normal Saline 3mL intravenous (peripheral line) or 10mL intravenous (central line) before and after infusion, or as needed for line patency
- Heparin 10 units per mL 3mL intravenous (peripheral line maintained >1 day) as needed for final flush
- Heparin 100 units per mL 5mL intravenous (central line) as needed for final flush
- May flush with 20mL Normal Saline post infusion to clear drug from line

**Supplies:** *(please strike through if not required)*

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

**Quantity/Refills:** Dispense 1 treatment cycle supply or 1-month supply. Refill x 1 year unless noted otherwise.

Additional refills to be provided upon patient reassessment.

Other \_\_\_\_\_

**Skilled nursing:** Vyvgart IV and Vyvgart Hytrulo vials Visit as needed to establish venous access, administer medication and assess general status and response to therapy. Vyvgart Hytrulo prefilled syringe- Skilled nursing visits to educate patient on subcutaneous access, medication administration, use of supplies, therapy and disease state and to assess general status and response to therapy. Nurse to establish access to administer during training if needed. Patient to be discharged from nursing once teaching complete.

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

**Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)**SIGN  
HERE

Date

Dispense as written

Date

Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

# Prior Authorization Checklist

## Myasthenia Gravis

Providing Accredo with the documentation outlined in this checklist may increase the likelihood and speed of obtaining coverage for your patients.<sup>1</sup> Coverage criteria may vary by payer.

Referral Form (not required for electronic prescriptions)	
	Completed myasthenia gravis referral form (available at <a href="https://www.accredo.com">accredo.com</a> )
	Copies of front and back of all medical insurance and prescription benefit cards
Clinical Documents	
	History and Physical (H&P) and progress notes (within past 6 months) <sup>2</sup> Note: Diagnosis of the disorder must be unequivocal
Myasthenia Gravis (MG)	
	Tensilon test results
	Tried and failed medications, or has contraindication to immunosuppressant therapies (e.g., Mestinon®/corticosteroids/azathioprine/cyclosporine/mycophenolate)
	Ongoing immunoglobulin (Ig) treatment must be documented in H&P and progress notes <sup>2</sup>
	Myasthenic Panel (MG Testing)
	History and Physical (H&P) and progress notes presenting acute myasthenic crisis and decompensation (respiratory failure or disabling weakness). Include Myasthenia Gravis-Specific Activities of Daily Living scale (MG-ADL)
	Clinical assessment that indicates eye muscle weakness, ptosis or swallowing issues
	Medication is prescribed by or in consultation with a neurologist

**Fax completed form to 866.233.7151.**

**If you have any questions, please call your Accredo Provider Support Advocate, or call 866.820.4844.**

1. This myasthenia gravis checklist is based on Medicare Part D guidelines and evidence of disease symptoms related to myasthenia gravis.
2. Ongoing management and documentation requirements:
  - a. Initial improvement and continued need must be meticulously documented in progress notes
  - b. All weaning must be attempted and documented as either amount or frequency